Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of bortezomib plus CHEP in untreated peripheral T-cell lymphoma
ChiCTR1900024800Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jul 2019
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in peripheral T-cell lymphoma (PTCL), sponsored by Zhejiang Cancer Hospital. Primary endpoints: response rate and toxicity. Started Jul 2019; status: recruiting.
02
Drugs
bortezomib
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on ChiCTR1900024800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024800.